Evidence Library

Showing 10 of 112 results.
Timothy Malloy, JD •
University of California, Los Angeles, School of Law

Regulators are implementing new programs that require manufacturers of products containing certain chemicals of concern to identify, evaluate, and adopt viable, safer alternatives. Such programs raise the difficult question for policymakers and regulated businesses of which alternatives are “viable” and “safer.” To address that question, these programs use “alternatives analysis,” an emerging methodology that integrates issues of human health and environmental effects with technical feasibility and economic impact.

 
Timothy Malloy, JD •
University of California, Los Angeles, School of Law

Emerging "prevention-based" approaches to chemical regulation seek to minimize the use of toxic chemicals by mandating or directly incentivizing the adoption of viable safer alternative chemicals or processes. California and Maine are beginning to implement such programs, requiring manufacturers of consumer products containing certain chemicals of concern to identify and evaluate potential safer alternatives. This article identifies an integrated set of design principles for regulatory alternatives analysis, and illustrates the application of those principles.

 
Lainie Rutkow, JD, PhD •
Johns Hopkins University Bloomberg School of Public Health
Caleb Alexander, MD, MS •
Johns Hopkins University Bloomberg School of Public Health

The study finds Florida’s efforts to prevent inappropriate use of painkillers are showing reductions among prescribers and patients who had the highest prescribing and usage rates.

 
Barbara Dennison, MD •
Health Research Inc./New York State Department of Health

The study reviewed policies from all 129 NY hospitals providing maternity care services. In 2009, none were fully compliant with WHO recommendations, but by 2013, 97, or 75 percent of the hospitals had compliant hospital breastfeeding policies. And as of April 2014, all 129 hospitals in New York had a fully compliant, approved, written breastfeeding policy in place.

 
Corey Davis, JD, MSPH •
University of North Carolina at Chapel Hill

Researchers reviewed 47 prescription monitoring program (PMP) websites for overdose content. They found that most PMPs did not address overdose or related terms in available materials and few state PMPs project overdose-specific messaging or provider tools for prevention.

 
Ameet Sarpatwari, JD, PhD •
Brigham and Women’s Hospital Inc.
Aaron Kesselheim, MD, JD, MPH •
Brigham & Women’s Hospital

In a Perspective for the New England Journal of Medicine, Sarpatwari and Kesselheim discuss the future of follow-on biologics in the United States. Among other issues, the article discusses the impact that so-called carve-outs from state drug product selection laws will have on reducing the market penetration of interchangeable biologics.

 
Lainie Rutkow, JD, PhD •
Johns Hopkins University Bloomberg School of Public Health

A new study released on March 2, 2015, in Health Affairs reports that most primary care physicians are aware of prescription drug monitoring programs and have used the data in their practices, but do so only intermittently.

The study surveyed 420 physicians randomly identified through the American Medical Association’s Masterfile list. Of those physicians surveyed, 72 percent were aware of their state’s prescription drug monitoring program, and 53 percent reported that they had used the programs.

 
Scott Rhodes, PhD •
Wake Forest University
Mark Hall, JD •
Wake Forest University

Section 287(g) of the Immigration and Nationality Act allowed states and localities to enforce federal immigration laws. This study finds that the state-level enforcement of this law has had an adverse impact on the use of pregnancy and childcare-related health services by Hispanic and Latina women.

 

Pages